Nektar Therapeutics (NKTR) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $57.55 -5.61%
EPS Growth %: -215.1%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -215.1%
Financial Fact:
Net loss: -43.22M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $32.77 million versus the consensus estimate of $30.47 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
